Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations
Source abstract
Abstract
The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung cancer. The liposomes were prepared by using solvent evaporation method. Various parameters such as particle size, zeta potential, entrapment efficiency, stability and in vitro drug release were determined. The size of liposomes (both conventional and modified) was 103.5 and 121.4 nm. The zeta potential and EE of both liposomes were -7.1 ± 1.3 mV, -1.2 ± 0.5 mV and (82.3 ± 1.9)%, (83.4 ± 1.5)%, respectively. It was found that modified liposomes increase the size of particles. The in vitro release results indicated that the release of erlotinib from galactosylated liposomes was similar to that of conventional liposome, demonstrating that the modification did not affect erlotinib release. From the result of in vivo, it proved that erlotinib liposomes can significantly improve the drug targeting, rapidly distribute the drug in the body, prolong the drug circulation time and significantly increase the relative bioavailability of the drug. Biodistribution studies showed that erlotinib from galactosylated liposomes had higher AUC inside liver than the injection group and no histological change occurred to the rat liver after the administration of erlotinib conventional and galactosylated liposomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Lung Cancer Research Studies · Peptidase Inhibition and Analysis · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;
Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
References (28)
Show source-provided references
1. International Agency for Research on Cancer, World Health Organization · 2012
2. 10.1053/j.gastro.2011.12.06110.1053/j.gastro.2011.12.061 ↗
3. 10.1159/00033901610.1159/000339016 ↗
4. 10.1007/s12032-012-0381-y10.1007/s12032-012-0381-y ↗
5. 10.1080/21691401.2017.137428210.1080/21691401.2017.1374282 ↗
6. Von Pawel J. · Bull Cancer · 2004 · 91 · E70
7. 10.2174/15680261179586092410.2174/156802611795860924 ↗
8. Clay D · P and T · 2005 · 30 · 561
9. 10.1016/j.clinthera.2005.10.01410.1016/j.clinthera.2005.10.014 ↗
10. 10.1016/j.ejim.2009.07.00910.1016/j.ejim.2009.07.009 ↗
11. 10.1200/JCO.2005.14.69610.1200/JCO.2005.14.696 ↗
12. 10.1002/cncr.2288610.1002/cncr.22886 ↗
13. 10.1200/JCO.2008.18.330110.1200/JCO.2008.18.3301 ↗
14. 10.1159/00033596310.1159/000335963 ↗
15. 10.1002/cncr.2655610.1002/cncr.26556 ↗
16. 10.2165/00003088-200544110-0000410.2165/00003088-200544110-00004 ↗
17. 10.1007/s00280-009-1133-310.1007/s00280-009-1133-3 ↗
18. 10.1080/21691401.2017.136032410.1080/21691401.2017.1360324 ↗
19. 10.1016/j.ijpharm.2012.06.02610.1016/j.ijpharm.2012.06.026 ↗
20. 10.1002/adhm.20120007910.1002/adhm.201200079 ↗
21. 10.1155/2011/72724110.1155/2011/727241 ↗
22. Bardania H · Artif Cells Nanomed Biotechnol · 2017 · 17 · 1
23. 10.1146/annurev.bi.51.070182.00253110.1146/annurev.bi.51.070182.002531 ↗
24. 10.2741/wu210.2741/wu2 ↗
25. Eliaz RE · Cancer Res · 2001 · 61 · 2592
26. 10.1016/0014-5793(92)80947-F10.1016/0014-5793(92)80947-F ↗
27. Bolandnazar S · Adv Pharm Bull · 2013 · 3 · 289
28. 10.1002/bmc.281410.1002/bmc.2814 ↗